Bristol-Myers Squibb Surges to 86th Most Traded Stock with $1.221 Billion Turnover

On May 12, 2025, Bristol-Myers Squibb (BMY) saw a significant surge in trading volume, with a total turnover of $1.221 billion, marking a 75.35% increase from the previous day. This substantial rise in trading activity positioned BMY as the 86th most traded stock of the day, reflecting heightened investor interest and market activity around the company's recent developments.

In the first quarter of 2025, Bristol-Myers Squibb reported revenue of $11.2 billion, surpassing analyst estimates of $10.78 billion. This performance, despite a 5.6% year-on-year decline, was driven by the company's growth portfolio, which offset declines in other areas. The revenue beat by 3.9% highlights the company's strategic initiatives and operational resilience.

CytomX Therapeutics, a collaborator of Bristol-Myers Squibb, reported a significant increase in revenue, primarily due to a higher percentage of completion for research programs within their collaboration. This collaboration has been a key driver of revenue growth for both companies, underscoring the strategic importance of their partnership.